These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36223209)

  • 21. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
    Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is shorter also better in the treatment of Clostridioides difficile infection?
    Duricek M; Halmova K; Krutova M; Sykorova B; Benes J
    J Antimicrob Chemother; 2024 Jun; 79(6):1413-1417. PubMed ID: 38661207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutics for
    Khanna S; Voth E
    Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
    Mullane KM; Miller MA; Weiss K; Lentnek A; Golan Y; Sears PS; Shue YK; Louie TJ; Gorbach SL
    Clin Infect Dis; 2011 Sep; 53(5):440-7. PubMed ID: 21844027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
    Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
    Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.